FDA’s Drug Monitoring Slammed in Report
GAO: Post-Vioxx Scandal, Agency Gives Decision-Making Power to Wrong Scientists
December 9, 2009
Back to Sanity on Cox-2 Drugs ; Patients, Doctors Can Weigh Risk, Rewards
If ever there were truth to the claim that one person's gain is another's pain it was in the FDA advisory panel's recent decision to allow Vioxx, Celebrex and Bextra - the easy-on- the stomach painkillers and anti-inflammatories known as Cox-2 inhibitors - to go back on the market.
Pulling Bextra Unlikely to Spark a Drug Scramble
When the popular painkiller Vioxx was taken off the market last fall, confusion ruled as doctors and patients scrambled for alternatives.
Panel: New Steps Needed To Ensure Drug Safety
Two years after the withdrawal of Vioxx, health regulators still lack the resources to track the safety of new drugs and respond to problems that might crop up, a panel of experts said Friday.
